Figure 3. Biphasic changes in [Ca2+]ER and Ca2+m following OGD/REOX.
A. [Ca2+]ER was determined in NKCC1+/+ astrocytes under normoxic control conditions and at 0–180 min REOX following 2 h OGD. In the bumetanide study, bumetanide (5 μM) was present during REOX. B. [Ca2+]ER was determined in NKCC1+/+ astrocytes treated with 2-APB, a nonspecific IP3R inhibitor (100 μM) during 0 min, 90 min, or 160 min REOX, or a specific IP3R inhibitor xestospongin C (20 μM, XeC). Data are means ± SEM; n = 3–9 (for XeC at 90 min REOX, n = 1). * p < 0.05 vs. normoxia, # p < 0.05 vs. OGD/REOX untreated; α p < 0.05 vs. 0 min REOX. C. Relative change in Ca2+m was determined in NKCC1+/+ and NKCC1−/− astrocytes under normoxic conditions or at 0–180 min of REOX. Data are means ± SEM; n = 3–5. * p < 0.05 vs. normoxia, # p < 0.05 vs. OGD/REOX. D. Relative change in Ca2+m was determined in NKCC1+/+ astrocytes under normoxic conditions or at 0–180 min of REOX. Xestospongin C (XeC, 20 μM) was present during REOX only. Data are means ± SEM; n = 8–35 cells. # p < 0.05 vs. OGD/REOX.